Microrna-34a suppresses malignant transformation by targeting c-myc transcriptional complexes in human renal cell carcinoma

Carcinogenesis

Volumn 33, Issue 2, 2012, Pages 294-300

  Yamamura, Soichiro ^a   Saini, Sharanjot ^a   Majid, Shahana ^a   Hirata, Hiroshi ^a   Ueno, Koji ^a   Chang, Inik ^a   Tanaka, Yuichiro ^a   Gupta, Ashish ^a   Dahiya, Rajvir ^a  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LUCIFERASE; MICRORNA; MICRORNA 34A; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; S PHASE KINASE ASSOCIATED PROTEIN 2; TRANSCRIPTION ELONGATION FACTOR; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; CELL FUNCTION; CELL INVASION; COMPLEX FORMATION; DOWN REGULATION; GENE TARGETING; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MALIGNANT TRANSFORMATION; ONCOGENE; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN ASSEMBLY; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION;

EID: 84863415971     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr286     Document Type: Article

References (45)

1. Brodersen, P. et al. (2009) Revisiting the principles of microRNA target recognition and mode of action. Nat. Rev. Mol. Cell Biol., 10, 141-148.
2. Croce, C. M. (2009) Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet., 10, 704-714.
3. Raver-Shapira, N. et al. (2007) Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol. Cell, 26, 731-743.
4. Chang, T. C. et al. (2007) Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol. Cell, 26, 745-752.
5. He, L. et al. (2007) A microRNA component of the p53 tumour suppressor network. Nature, 447, 1130-1134.
6. Li, Y. et al. (2009) MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res., 69, 7569-7576.
7. Welch, C. et al. (2007) MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene, 26, 5017-5022.
8. Liu, C. et al. (2011) The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat. Med., 17, 211-215.
9. Yamakuchi, M. et al. (2008) miR-34a repression of SIRT1 regulates apoptosis. Proc. Natl Acad. Sci. USA, 105, 13421-13426.
10. Liu, H. et al. (2011) Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma. BMC Syst. Biol., 4, 51
11. Vogt, M. et al. (2011) Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Virchows Arch., 458, 313-322.
12. Adhikary, S. et al. (2005) Transcriptional regulation and transformation by Myc proteins. Nat. Rev. Mol. Cell Biol., 6, 635-645.
13. Cole, M. D. et al. (2008) Transcription-independent functions of MYC: regulation of translation and DNA replication. Nat. Rev. Mol. Cell Biol., 9, 810-815.
14. O'Donnell, K. A. et al. (2005) c-Myc-regulated microRNAs modulate E2F1 expression. Nature, 435, 839-843.
15. He, L. et al. (2005) A microRNA polycistron as a potential human oncogene. Nature, 435, 828-833.
16. Olive, V. et al. (2009) miR-19 is a key oncogenic component of mir-17-92. Genes Dev., 23, 2839-2849.
17. Cannell, I. G. et al. (2010) p38 MAPK/MK2-mediated induction of miR-34c following DNA damage prevents Myc-dependent DNA replication. Proc. Natl Acad. Sci. USA, 107, 5375-5380.
18. Christoffersen, N. R. et al. (2010) p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. Cell Death Differ., 17, 236-245.
19. Etienne-Manneville, S. et al. (2002) Rho GTPases in cell biology. Nature, 420, 629-635.
20. Heasman, S. J. et al. (2008) Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat. Rev. Mol. Cell Biol., 9, 690-701.
21. Jaffe, A. B. et al. (2005) Rho GTPases: biochemistry and biology. Annu. Rev. Cell Dev. Biol., 21, 247-269.
22. Hodge, J. C. et al. (2003) Requirement of RhoA activity for increased nuclear factor kappaB activity and PC-3 human prostate cancer cell invasion. Cancer Res., 63, 1359-1364.
23. Cardone, R. A. et al. (2005) Protein kinase A gating of a pseudopodiallocated RhoA/ROCK/p38/NHE1 signal module regulates invasion in breast cancer cell lines. Mol. Biol. Cell, 16, 3117-3127.
24. Xia, M. et al. (2007) Tumor suppressor p53 restricts Ras stimulation of RhoA and cancer cell motility. Nat. Struct. Mol. Biol., 14, 215-223.
25. Chan, C. H. et al. (2010) Deciphering the transcriptional complex critical for RhoA gene expression and cancer metastasis. Nat. Cell Biol., 12, 457-467.
26. Peterlin, B. M. et al. (2006) Controlling the elongation phase of transcription with P-TEFb. Mol. Cell, 23, 297-305.
27. Bres, V. et al. (2008) The multi-tasking P-TEFb complex. Curr. Opin. Cell Biol., 20, 334-340.
28. Eberhardy, S. R. et al. (2002) Myc recruits P-TEFb to mediate the final step in the transcriptional activation of the cad promoter. J. Biol. Chem., 277, 40156-40162.
29. Kanazawa, S. et al. (2003) c-Myc recruits P-TEFb for transcription, cellular proliferation and apoptosis. Oncogene, 22, 5707-5711.
30. Rahl, P. B. et al. (2010) c-Myc regulates transcriptional pause release. Cell, 141, 432-445.
31. Eberhardy, S. R. et al. (2001) c-Myc mediates activation of the cad promoter via a post-RNA polymerase II recruitment mechanism. J. Biol. Chem., 276, 48562-48571.
32. Gargano, B. et al. (2007) P-TEFb is a crucial co-factor for Myc transactivation. Cell Cycle, 6, 2031-2037.
33. Meyer, N. et al. (2008) Reflecting on 25 years with MYC. Nat. Rev. Cancer, 8, 976-990.
34. Brooks, T. A. et al. (2009) The role of supercoiling in transcriptional control of MYC and its importance in molecular therapeutics. Nat. Rev. Cancer, 9, 849-861.
35. Land, H. et al. (1983) Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature, 304, 596-602.
36. Sahai, E. et al. (2002) RHO-GTPases and cancer. Nat. Rev. Cancer, 2, 133-142.
37. Shiio, Y. et al. (2002) Quantitative proteomic analysis of Myc oncoprotein function. EMBO J., 21, 5088-5096.
38. Berenjeno, I. M. et al. (2007) Transcriptomal profiling of the cellular transformation induced by Rho subfamily GTPases. Oncogene, 26, 4295-4305.
39. Watnick, R. S. et al. (2003) Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell, 3, 219-231.
40. Sauzeau, V. et al. (2010) A transcriptional cross-talk between RhoA and c-Myc inhibits the RhoA/Rock-dependent cytoskeleton. Oncogene, 29, 3781-3792.
41. Chao, S. H. et al. (2001) Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J. Biol. Chem., 276, 31793-31799.
42. Zhou, Q. et al. (2006) The Yin and Yang of P-TEFb regulation: implications for human immunodeficiency virus gene expression and global control of cell growth and differentiation. Microbiol. Mol. Biol. Rev., 70, 646-659.
43. Mueller, D. et al. (2009) Misguided transcriptional elongation causes mixed lineage leukemia. PLoS Biol., 7, e1000249
44. Lin, C. et al. (2010) AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol. Cell, 37, 429-437.
45. Moiola, C. et al. (2010) Cyclin T1 overexpression induces malignant transformation and tumor growth. Cell Cycle, 9, 3119-3126.